Opportunity Analysis and Industry Forecast, 2016-2023 3D Printed Drugs Market Global Opportunity Analysis and Industry Forecast, 2017-2030
Dysphagia is more prevalent in geriatric population and children, which results in difficulty while swallowing. 3D printed drugs are gaining popularity, as FDA has passed a priority review voucher system for it. In addition, increase in geriatric population and technological advancement in 3D pointing procedures are expected to contribute towards the growth of the market. Pallavi Jaiswal
3D PRINTED DRUGS MARKET OVERVIEW 3D Printed Drugs Market are medications, which are designed by 3D printing technique to customize for the individuals in a safer and effective way. These drugs have unitary porous structures that readily disperse in the mouth, as a result of which these high-dose medicines need not to be swallowed intact. Thus, this form of medication is helpful to patients who often have swallowing difficulties, children, elderly, and those dealing with the complications of stroke, Alzheimers disease, head & neck tumors, and other neurological disorders. The first 3D printed drug to receive approval from the U.S. Food and Drug Administration (FDA) is Spritam (levetiracetam) tablets developed by Aprecia Pharmaceuticals. The potential market for other 3D printed drugs (moderate growth scenario) is estimated to be $278 million in 2020, and would reach $522 million by 2030, growing at a CAGR of 6.5% from 2020 to 2030.
3D PRINTED DRUGS MARKET According to a new report published by Allied Market Research, titled, 3D Printed Drugs Market by Forecast Scenario Analysis: Global Opportunity Analysis and Industry Forecast, 2017-2030, Spritam is the only 3D printed drug available in the market since 2016 to treat epilepsy. The potential market for other 3D printed drugs (moderate growth scenario) is estimated to be $278 million in 2020, and would reach $522 million by 2030, growing at a CAGR of 6.5% from 2020 to 2030. U.S. market holds the highest market share in 2020. Access Full Summary at: https://www.alliedmarketresearch.com/3d-printed-drugs-market 3D printed drugs are medications created by 3D printing technology that are used to treat patients suffering from dysphagia. 3D printed drugs have porous structures that can disintegrate rapidly inside the mouth itself. Aprecia Pharmaceuticals Companys SPRITAM levetiracetam is the first 3D printed drug, which has been approved by the U.S. Food and Drug Administration (FDA) in August 2015.
3D PRINTED DRUGS MARKET Constant technological developments in 3D printing technique, rise in incidence of epilepsy cases, and increase in awareness about the 3D printing technology in the developing countries drive the growth of the market. However, lack of government regulations related to these drugs and adverse effects of 3D printed drugs are expected to limit the market growth. For Sample Request at: https://www.alliedmarketresearch.com/request-sample/4508 The global 3D printed drugs market is analyzed based on forecast scenario such as low growth scenario, moderate growth scenario, and rapid growth scenario. According to low growth scenario, the U.S. is anticipated to account for the highest market share in 2020, and rest of North America market is expected to grow at the highest rate, registering the CAGR of 5.1% by 2030.
3D PRINTED DRUGS MARKET Europe is estimated to account for four-sevenths share in 2020, and is expected to dominate the market throughout the forecast period, due to presence of well-established healthcare systems and increase in prevalence of dysphagia. In addition, increase in adoption of 3D printed drugs is anticipated to provide new growth opportunities for the key players in the European market. However, Asia-Pacific is projected to grow at the highest growth rate during the analysis period, owing to increase in healthcare expenditure, rise in awareness related to 3D printing technique, presence of large patient pool, and developments in healthcare infrastructure.
3D PRINTED DRUGS MARKET SNAPSHOT The major driver of the LAMEA other 3D printed drugs market include rise in prevalence of dysphagia. Brazilian Journal of Otorhinolaryngology reported that in 2017 approximately 65 million people were affected by dysphagia in Brazil, that is, around 35.9% of total population of Brazil. Thus, increasing number of people suffering from dysphagia and developing healthcare facilities are expected to fuel the market growth. In addition, technological advancement in the region, increase in affordability, and rise in awareness towards 3D printing technique fuel the market growth. Moreover, increase in funds by government organizations to improve the healthcare infrastructure propels the growth of the 3D printed drugs market in LAMEA.
3D PRINTED DRUGS MARKET KEY BENIFITS Key Benefits The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets. The report provides information about the current and upcoming trends in the market from 2016 to 2023, which helps to determine the prevailing opportunities. Comprehensive analysis of factors that drive and restrict the growth of the market is provided. Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale are provided. Key market players within the market are profiled in this report and their strategies are analyzed thoroughly, which help understand the competitive outlook of the global market.
KEYFINDING 3D PRINTED DRUGS MARKET In North America, the U.S. is anticipated to dominate the market in 2020, whereas rest of North America is projected to grow at the highest CAGR during the forecast period. Germany was the major shareholder in the European 3D printed drugs market in 2016. Asia-Pacific is expected to register the highest growth rate in future. Australia is expected to grow at the highest CAGR in the Asia-Pacific 3D printed drugs market. The key players profiled in this report include Aprecia Pharmaceuticals, GlaxoSmithKline Plc., Hewlett Packard Caribe, BV, LLC, 3D Printer Drug Machine, and FabRx Ltd. The organizations engaged in the research of 3D printed drugs included in this report are UCL School of Pharmacy, University of Glasgow, University College London, The University of Nottingham, and National University of Singapore.
3D PRINTED DRUGS MARKET BY GEOGRAPHY North America Europe Asia-Pacific LAMEA
3D PRINTED DRUGS MARKET Thank You! For More Details Visit us at https://www.alliedmarketresearch.com/3d-printed-drugs-market Follow Us On